I n patients undergoing percutaneous coronary intervention (PCI), the prevalence of atrial fibrillation (AF) is substantial and may be increasing (1). An indication for oral anticoagulation, such as AF, in patients who require antiplatelet therapy for PCI can make therapeutic choices difficult (2). Previous investigation has shown that the combination of oral anticoagulation and antiplatelet therapy increases the risk of bleeding (3-6). However, there are few data on the combination of direct oral anticoagulants with dual antiplatelet therapy (DAPT) in the post-PCI setting. In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (7) , patients taking DAPT were excluded from enrollment, but participants who underwent PCI during the conduct of the trial were allowed to continue study drug and the use of antiplatelet therapy, as well as duration, was left to the investigators' discretion.
To understand more about the combination of rivaroxaban and antiplatelet therapy in the post-PCI setting, we analyzed patients in the ROCKET AF trial who underwent PCI during the study. We aimed first to describe the incidence of PCI and characteristics of the population that required PCI during the ROCKET AF trial. We then aimed to describe the patterns of antiplatelet therapy in the post-PCI setting, and finally the clinical outcomes of patients undergoing PCI and on combinations of oral anticoagulation and antiplatelet therapy.
METHODS STUDY POPULATION. The ROCKET AF trial design, methods, and primary results have been published (7, 8) . Briefly, ROCKET AF was a randomized, double-blind, double-dummy international noninferiority trial that compared fixed-dose rivaroxaban undergoing PCI were similar in age, but less often female, more likely to have been on prior vitamin K antagonist agents, and more likely to have had a prior MI or diabetes compared with patients who did not undergo PCI ( Table 1 ).
FREQUENCY OF PCI AND PROCEDURAL CHARACTERISTICS.
There was a consistently small but increasing incidence of PCI over time ( Figure 1) . Warfarin-treated patients had a significantly shorter time (273 vs. 370 days; p ¼ 0.011) to first PCI compared with the rivaroxaban-treated patients, and warfarin-treated patients were more likely to undergo PCI during the conduct of the trial. For procedural characteristics, the use of bare metal stents was slightly higher than the use of drug-eluting stents, and a minority of patients received balloon angioplasty alone ( Table 2) . (Table 3) . Similar patterns were seen for bleeding outcomes; patients with PCI were at substantially greater risk for bleeding events compared with those who did not undergo PCI ( Table 3) . On comparison of the treatment groups, there was a numerically higher rate of stroke and vascular death events in the warfarin group compared with the rivaroxaban group (Table 4 ). The risk of the composite outcome of stroke and systemic embolism was similar between treatment groups as was the risk of MI. For bleeding events, there was a numerically increased rate of both major bleeding and the composite of major and clinically relevant nonmajor bleeding in those treated with rivaroxaban compared with those treated with warfarin ( Table 4) . When patients were divided by use of antiplatelet therapy at 30 days after PCI, the rates of major bleeding were high and similar across treatment groups for all patients (Online Table 2 ) and for those patients who remained on study drug (81%) (Online Table 3 ). Values are n (%).
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); other abbreviation as in Table 1 . Sherwood et al. Abbreviation as in Tables 1 and 3 .
FIGURE 4 Proportion of Adverse Events After PCI
There is a clustering of events in the 6-month time window. Abbreviation as in Figure 1 . Dual Antiplatelet Therapy and Outcomes in PCI A U G U S T 2 2 , 2 0 1 6 : WHAT IS NEW? We studied the antithrombotic therapy practice patterns and outcomes in patients undergoing PCI during the ROCKET AF trial. In patients with AF at moderate-to-high risk for stroke, PCI occurred in <1% per year. Dual antiplatelet therapy was used in a variable manner, with the majority of patients remaining on the study drug after PCI. Rates of both thrombotic and bleeding events were high after PCI, highlighting the need for studies to determine the optimal antithrombotic therapy for patients requiring OAC who undergo PCI.
WHAT IS NEXT? Several ongoing studies are investigating the optimal combination of DOACs and antiplatelet therapy. Sherwood et al.
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